SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Pieris Pharmaceuticals, Inc. (PIRS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PIRS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.71
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-43.73 |
$5.83M |
$-22.8M |
-391% |
| 2017 |
$-32.14 |
$25.28M |
$-17.65M |
-69.8% |
| 2018 |
$-40.32 |
$29.1M |
$-26.75M |
-91.9% |
| 2019 |
$-37.54 |
$46.28M |
$-23.76M |
-51.3% |
| 2020 |
$-54.67 |
$29.32M |
$-37.23M |
-127% |
| 2021 |
$-53.75 |
$31.42M |
$-43.37M |
-138% |
| 2022 |
$-33.71 |
$25.9M |
$-31.25M |
-120.7% |
| 2023 |
$-21.80 |
$42.81M |
$-24.54M |
-57.3% |
| 2024 |
$-7.83 |
$0.00 |
$-17.43M |
- |
| 2025 |
$-3.71 |
$0.00 |
$-41.72M |
- |
